Robert Hopkins and Arun Upadhyay take senior roles at Ocugen

1 September 2022

Ocugen (Nasdaq: OCGN), a US biotech focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, has announced the appointment of Robert Hopkins as chief medical officer (CMO) and Arun Upadhyay as chief scientific officer (CSO).

Dr Hopkins has more than 25 years experience as a physician and clinical researcher. In addition to his work in government organizations, he has held senior level positions at Merck Research Labs, DynPort Vaccine Company, Emergent BioSolutions (NYSE: EBS), and Aeras. He has developed and commercialized multiple vaccine and therapeutic products, from Phase I through IV.

"I look forward to bringing my vaccines and therapeutics experience to Ocugen," said Dr Hopkins. “It’s imperative that we provide additional options in the fight against COVID-19, as well as deliver new gene and cell therapies to address unmet medical need."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK